ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
| Revenue (TTM) | $978.38M |
| Gross Profit (TTM) | $590.98M |
| EBITDA | $209.41M |
| Operating Margin | 15.00% |
| Return on Equity | 20.50% |
| Return on Assets | 5.45% |
| Revenue/Share (TTM) | $47.24 |
| Book Value | $27.87 |
| Price-to-Book | 2.86 |
| Price-to-Sales (TTM) | 1.74 |
| EV/Revenue | 1.987 |
| EV/EBITDA | 7.94 |
| Quarterly Earnings Growth (YoY) | 191.10% |
| Quarterly Revenue Growth (YoY) | 25.90% |
| Shares Outstanding | $22.96M |
| Float | $19.66M |
| % Insiders | 5.42% |
| % Institutions | 107.06% |
Volatility is currently expanding
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®.
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANIP and any ticker you trade — then tracks every position and per-strategy win rate.
